

Institutional Review Board (IRB) statement

Paris, January 29, 2015

Dear Mr Tian,

As requested I send you the document signed concerning the manuscript "Disease Control with Sunitinib in Advanced Intrahepatic Cholangiocarcinoma Resistant to Gemcitabine-oxaliplatin Chemotherapy."

I, the corresponding author, Mohamed BOUATTOUT certify that:

since single cases of compassionate of already marketed drugs used off-labeled do not require The Institutional Review Board (IRB) approval in France.

Mohamed BOUATTOUT; MD.

Department of Hepatology and Medical Oncology, Beaujon University Hospital.